Serum levels of 14‑3‑3η are associated with increased disease risk, activity and duration of rheumatoid arthritis in Chinese patients

Tu, Jianxin; Chen, Xiaowei; Dai, Meijie; Pan, Axiao; Liu, Cailong; Zhou, Yan; Xia, Xiaoru; Lee, Sun

doi:10.3892/etm.2020.8761

Cited by 6 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…46 14-3-3η predicts disease activity of RA and its duration, and when combined with other biomarkers such as anti-CCP and RF, its diagnostic ability improves. [25][26][27] This has also been consistent with previous studies. 47 14-3-3η is a predictor of bone remodelling and RA related osteoporosis.…”

Section: Discussionsupporting

confidence: 93%

“…The level of 14-3-3η was highest in the osteoporosis group compared to the normal group (p<0.05). 25 Similarly, another study showed that 14-3-3η positively correlated with inflammation and disease risk as reported by Tu J et al 26 14-3-3η was significantly increased in RA patients, and ROC analysis indicated that it served as a potential predictive marker for RA risk. 26 14-3-3η distinguished patients with established RA (disease duration >2 years) compared to early RA patients ([?…”

Section: Resultsmentioning

confidence: 59%

“…14-3-3η correlated with other inflammatory markers such as RF and anti-CCP suggesting it may serve as a biomarker for disease risk. 26 Also, a study by Hu T et al, explored the clinical value of a collagen triple helix repeat containing 14-3-3η protein as a component and found that 14-3-3η had the largest odds ratio at 5.1 (95% CI 2.1 to 12.5) for RA diagnosis. They also reported that a combination of anti-CCP and 14-3-3η has a diagnostic value of RA.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Biomarkers for the diagnosis and treatment of rheumatoid arthritis-a systematic review

Abdelhafiz¹,

Baker²,

galscow³

2021

Preprint

View full text Add to dashboard Cite

Background Rheumatoid Arthritis (RA) is an autoimmune disease, symmetrically affecting the small joints. Biomarkers are tools that can be used in the diagnosis and monitoring of RA. Aim To systematically explore the role of the biomarkers: C-reactive protein (CRP), Rheumatoid factor (RF), Anti-cyclic citrullinated protein (Anti-CCP), 14-3-3η and the multi-biomarker disease activity (MBDA) score for the diagnosis and treatment of RA. Methods A systematic review of the English literature using four different databases was carried out. Results CRP>7.1 mg/L predicted poor conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) outcome in RA. Anti-CCP, CRP ≥0.3 mg/dL and RF predicted bone erosion and cartilage destruction. Combination of high 14-3-3η with RF and CRP improved the prediction of rapid erosion progression (REP). Anti-CCP was not associated with disease activity, but was associated with increased radiographic damage (r=0.46, p=0.048). RF was not associated with joint damage but correlated with ultrasound-detected bone erosion. 14-3-3η significantly correlated with inflammation, bone remodelling and osteoporosis in RA patients (p<0.05). 14 3 3η positively correlated with RA duration (p=0.003), disease activity and positive RF (P=0.025) and it distinguished early from established RA. Early MBDA scores correlated with later response in disease activity, after 6 and 12 weeks of treatment (p<0.05). MBDA score was able to differentiate between small differences in disease activity and predicted remission over one year period. Conclusion The investigated biomarkers are helpful tools in clinical practice for diagnosis, monitoring of treatment and predicting prognosis in RA patients. However, further research is still required to investigate novel biomarkers for the pre-treatment selection of potentially responsive patients before starting therapy for a precision medicine in this area.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Resultsmentioning

confidence: 59%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers for the diagnosis and treatment of rheumatoid arthritis-a systematic review

Abdelhafiz¹,

Baker²,

galscow³

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…In Japanese patients with established RA, patients with positive 14-3-3η had a significantly higher DAS28 score, ESR level and CRP level than patients with negative 14-3-3η [9]. Tu et al [24] found that RA patients had a significantly higher serum 14-3-3η protein level than in osteoarthritic patients and control individuals.…”

Section: Discussionmentioning

confidence: 98%

14-3-3η protein is associated with disease activity and osteoporosis in patients with rheumatoid arthritis

Sadeq¹

2022

Reumatologia

View full text Add to dashboard Cite

ObjectivesThis study was designed to explore the potential association of serum 14-3-3η protein level with disease activity and bone mineral density (BMD) in Egyptian patients with rheumatoid arthritis (RA). Patients were recruited from the outpatient clinic at Mansoura University Hospital.Material and methodsOne hundred eighty-eight patients with RA and 192 matched controls were enrolled. The rheumatoid arthritis activity parameters were evaluated in RA patients. Bone mineral density was measured. Serum levels of 14-3-3η protein and IL-6 were estimated for all participants by enzyme-linked immunosorbent assays (ELISA).ResultsRheumatoid arthritis patients had a significantly higher median serum 14-3-3η protein level compared to matched controls (p ≤ 0.05). Serum level of 14-3-3η protein was significantly correlated with DAS28–ESR (p ≤ 0.05) and serum IL-6 level (p ≤ 0.05). The rheumatoid arthritis-osteoporosis group had significantly higher serum 14-3-3η protein than the RA-osteopenia group and RA-control group. Similarly, the difference of the serum 14-3-3η protein between the RA-osteopenia group and the RA-control group was significant. In the linear regression analysis, the strongest factors that were associated with BMD in RA patients were the serum level of 14-3-3η protein (p ≤ 0.05), IL-6 (p ≤ 0.05) and DAS28–ESR (p ≤ 0.05).ConclusionsSerum level of 14-3-3η protein was significantly elevated in RA patients compared to controls and is significantly correlated with parameters of activity disease. The RA-osteoporosis group had significantly higher serum 14-3-3η protein than the RA-osteopenia group and RA-control group. Serum 14-3-3η protein can be a promising biomarker to reflect RA activity and predict presence of osteoporosis in RA patients.

show abstract

“…For instance, a previous study demonstrated that 14-3-3η may be involved in the pathogenesis of RA via promoting the formation of invadosomes through regulating the forkhead box O3/Snail axis ( 34 ). In another study, the serum levels of 14-3-3η were associated with an increased risk of RA and disease severity ( 35 ). Of note, emerging evidence has suggested that 14-3-3η serves a vital role in bone metabolism ( 13 , 19 ).…”

Section: Discussionmentioning

confidence: 99%

Serum 14‑3‑3η levels are increased and associated with a higher risk of osteoporosis in patients with rheumatoid arthritis: A meta‑analysis

Fan,

Zhou,

et al. 2023

Exp Ther Med

View full text Add to dashboard Cite

14-3-3η can regulate the cell cycle, immunity, inflammation and the secretion of matrix metalloproteinases, while it may also be involved in the development of rheumatoid arthritis (RA) and promote bone injury. Therefore, the present meta-analysis focused on the dysregulated serum levels of 14-3-3η and its association with osteoporosis in patients with RA. Studies comparing the serum levels of 14-3-3η between patients with RA and healthy controls (HCs) or patients with RA with different bone mineral densities were retrieved from the EMBASE, Web of Science, PubMed and Cochrane databases. A total of 14 studies comprising 2,164 patients with RA and 1,136 HCs were included and analysed. Pooled analyses showed that the serum levels of 14-3-3η were enhanced in patients with RA compared with HCs [standardized mean difference (SMD): 1.34; 95% confidence interval (CI): 1.01-1.66; P<0.001]. In addition, the serum levels of 14-3-3η were also significantly higher in patients with RA with osteoporosis and osteopenia compared with those with normal bone mass (SMD: 1.96; 95% CI: 0.01-3.92; P=0.049 and SMD: 0.80; 95% CI: 0.09-1.52; P=0.028, respectively). Begg's and Egger's tests demonstrated that the publication bias for each evaluated indicator was low (all P>0.05). However, sensitivity analyses revealed that the findings were not very robust, which may be due to the omission of several individual studies. Overall, the present meta-analysis suggested that the serum levels of 14-3-3η were elevated and were associated with a higher risk of osteoporosis in patients with RA, thus supporting its potency as a circulating biomarker in the management of RA.

show abstract

Serum levels of 14‑3‑3η are associated with increased disease risk, activity and duration of rheumatoid arthritis in Chinese patients

Cited by 6 publications

References 35 publications

Biomarkers for the diagnosis and treatment of rheumatoid arthritis-a systematic review

Biomarkers for the diagnosis and treatment of rheumatoid arthritis-a systematic review

14-3-3η protein is associated with disease activity and osteoporosis in patients with rheumatoid arthritis

Serum 14‑3‑3η levels are increased and associated with a higher risk of osteoporosis in patients with rheumatoid arthritis: A meta‑analysis

Contact Info

Product

Resources

About